---
document_datetime: 2026-01-16 16:07:11
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: elrexfio-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 2.9845284
conversion_datetime: 2026-01-17 12:56:25.959087
docling_version:
  docling-serve: 1.10.0
  docling-jobkit: 1.8.1
  docling: 2.68.0
  docling-core: 2.59.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.3
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## ELREXFIO

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary        |
|----------------------|------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------|
| Variation type II /  | C.I HUMAN AND VETERINARY MEDICINAL | 13/11/2025                          |                                             | SmPC and PL                      | Not applicable |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000294591                        | PRODUCTS - C.I.4 Change(s) in the Summary of Product Characteristics, Labelling or Package Leaflet due to new quality, preclinical, clinical or pharmacovigilance data - Accepted Update of section 4.8 of the SmPC in order to add progressive multifocal leukoencephalopathy to the list of adverse drug reactions (ADRs) with the frequency uncommon based on clinical trials and post- marketing data-sources. In accordance with the updated data cut-off of September 10, 2024, the incidence rates for all listed adverse reactions have been revised. The Package Leaflet is updated accordingly.   |            |            |                 |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-----------------|
| Variation type IA_IN / EMA/VR/0000278463 | B.II.b.2.c Replacement or addition of a manufacturer responsible for importation and/or batch release - B.II.b.2.c.1 Not including batch control/testing - Accepted                                                                                                                                                                                                                                                                                                                                                                                                                                         | 11/09/2025 | 10/09/2025 | Annex II and PL |
| Variation type II / EMA/VR/0000280555    | B.I.a.1 Change in the manufacturer of a starting material/reagent/intermediate used in the manufacturing process of the active substance or change in the manufacturer (including where relevant quality control testing sites) of the active substance, where no Ph. Eur. Certificate of Suitability is part of the approved dossier - B.I.a.1.j Changes to quality control testing arrangements for a biological active substance: replacement or                                                                                                                                                         | 04/09/2025 | N/A        |                 |

<div style=\"page-break-after: always\"></div>

|                                       | addition of a site where batch control/testing including a biological / immunological / immunochemical method takes place - Accepted                                                                                                                                                                                                                                                                                                  |            |            |      |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
|---------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Renewal - 1 year / EMA/R/0000269600   | - Renewal - Accepted Renewal of marketing authorisation                                                                                                                                                                                                                                                                                                                                                                               | 24/07/2025 | 10/09/2025 |      | The CHMP, having reviewed the available information on the status of the fulfilment of Specific Obligations and having confirmed the positive benefit risk balance, is of the opinion that the quality, safety and efficacy of this medicinal product continue to be adequately and sufficiently demonstrated and therefore recommends the renewal of the conditional MA for ELREXFIO, subject to the Specific Obligations and Conditions as laid down in Annex II to the opinion. |
| Variation type IB / EMA/VR/0000285949 | This was an application for a group of variations. B.I.d.1.a Re-test period/storage period - B.I.d.1.a.4 Extension or introduction of a re- test period/storage period supported by real time data - Accepted B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.5 Extension of the shelf-life of a biological/ immunological medicinal product in accordance with an approved stability protocol - Accepted | 21/07/2025 | 10/09/2025 | SmPC |                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

| Variation type IB / EMA/VR/0000246959   | B.II.f.1.b Extension of the shelf life of the finished product - B.II.f.1.b.2 After first opening (supported by real time data) - Accepted                                                                                                                                                                                                                                                                                                                                                                                | 04/04/2025   | 10/09/2025   | SmPC and PL   |             |
|-----------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|--------------|---------------|-------------|
| Variation type IA / EMA/VR/0000237706   | A. ADMINISTRATIVE CHANGES - A.4 Change in the name and/or address of: a manufacturer (including where relevant quality control testing sites); or an ASMF holder; or a supplier of the active substance, starting material, reagent or intermediate used in the manufacture of the active substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted | 06/03/2025   | N/A          |               |             |
| PSUR / EMA/PSUR/0000268954              | - -                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |              |              |               | Maintenance |